P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.396
Abstract: In VARSITY, the first head-to-head randomized controlled trial of biologics, vedolizumab (VDZ) was superior vs adalimumab (ADA) in achieving clinical remission (CR) at Week 52 in patients (pts) with moderate to severe ulcerative colitis (UC).1… read more here.
Keywords: colitis; treatment; varsity; disease clearance ... See more keywords